Objectives: To determine the direct medical costs of hospitalizations for acute pancreatitis in the United States and analyze the demographic characteristics of hospitalized patients.
W e have recently described an increasing rate of US emergency department visits for acute pancreatitis from 1993 to 2003 and an increase in inpatient hospitalizations from 1988 to 2003. 1, 2 No studies have examined the cost of these admissions. To address this information gap, we analyzed data from the 2003 Healthcare Cost and Utilization ProjectYNational Inpatient Survey (HCUP-NIS), the largest publicly available all-payer inpatient care database in the United States and the only national hospital database containing charge information on all patients. Our primary objective was to define the cost of US hospital admissions for acute pancreatitis.
MATERIALS AND METHODS

Study Population
The 2003 HCUP-NIS is a federal state industry data system funded by the Agency for Healthcare Research and Quality. This cross-sectional survey examines a stratified random sample of US community hospitals (defined as all nonfederal, short-term, general, and other specialty hospitals, excluding hospital units of institutions) and is the largest allpayer inpatient care database that is publicly available in the United States; it is the only national hospital database containing charge information on all patients. 3, 4 Analysis of the HCUP-NIS data set was approved by the Massachusetts General Hospital's Institutional Review Board.
Study Protocol
The 2003 HCUP-NIS data were drawn from 37 participating states. A sampling frame of 3570 hospitals was stratified by geographic region, ownership control, teaching status, and bed size. Up to 20% of hospitals were randomly selected from within each stratum. Patient-level clinical and resource-use information typically available in a discharge abstract were included for all discharges from selected hospitals for the sample year. The final sample included 7,977,728 discharges from 994 hospitals. 3 Each discharge abstract included age, sex, race/ ethnicity, US region and division, primary payer, admission source, length of stay (LOS), disposition, median household income quartile, and up to 15 procedures and 15 discharge diagnoses. 3 Procedures and diagnoses were coded using both International Classification of Disease, 9th Edition, Clinical Modification (ICD-9-CM) codes and the Clinical Classifications Software, which was developed by the Agency for Healthcare Research and Quality to group ICD-9-CM codes into clinically sensible and mutually exclusive categories. 5 In this analysis, Ball pancreatitis^cases were identified when ICD-9-CM code 577.0 was identified in any of the 15 diagnoses fields, and Bprimary diagnosis^cases were identified when ICD-9-CM code 577.0 was identified in the primary diagnosis field. For both categories, we excluded cases where chronic pancreatitis (ICD-9-CM code 577.1) was identified in any of the 15 diagnostic fields.
Total costs were estimated by applying the HCUP-NIS cost-to-charge ratio (CCR) files. Each file contains hospitalspecific cost-to-charge ratios based on all-payer inpatient cost for nearly every hospital in the corresponding HCUP-NIS database. Cost information was obtained from the hospital accounting reports collected by the Centers for Medicare and Medicaid Services. Because of incomplete hospital CCR data, cases without hospital-specific CCR ratios were excluded, and data were appropriately reweighted to analyze costs.
3,4
Data Analysis
We determined point estimates and 95% confidence intervals (CIs) for patient characteristics, charges, and costs for US pancreatitis-related discharges. Nationally representative estimates were determined using NIS-assigned discharge weights appropriate for the 20% subsample, which adjusted for the probability of selection. Data are presented with number of observations for the 20% subsample and the corresponding weighted totals representative of all discharges in the United States.
Binomial and categorical variables were analyzed using weighted W 2 test. Differences in means were evaluated using a t statistic appropriate for survey data. Direct age standardization for survey data was used to calculate age-adjusted proportions for race and region. A multivariate linear regression of total costs was performed with predefined demographic, administrative, and treatment characteristics. All analyses were performed using appropriate survey commands to account for the stratified 2-stage sampling frame. Although cost data were skewed, we did not transform the data because of the very large size of the data set. Based on the central limit theorem, in a very large data set, the distribution of an average tends to be normal, even when the distribution from which the average is computed is decidedly nonnormal. 6 US visit rates were computed using midyear age, sex, race, ethnicity, and metropolitan status and regionspecific population estimates from the US Census Bureau; all rates were reported per 1000 individuals per year for the US resident population. 7Y9 All P values are 2-sided, with P G 0.05 considered statistically significant. Data analysis was performed using Stata version 9.0. (StataCorp, College Station, Tex).
RESULTS
The 2003 HCUP-NIS contained 14,346 records coded for acute pancreatitis in any diagnostic position without a codiagnosis of chronic pancreatitis. This represents approximately 344,000 (95% CI, 329,000Y358,000) total cases of acute pancreatitis. Estimated total charges for these hospitalizations were $11 billion (95% CI, $10Y12 billion), and estimated total costs were $4.3 billion (95% CI, $4.0Y4.7 billion). Including only records with acute pancreatitis listed as the primary diagnosis yielded 9408 records. These represented approximately 226,000 (95% CI, 216,000Y 235,000) cases, and these more strictly defined cases form the focus of all subsequent analyses. Estimated total charges for these admissions were $5.4 billion (95% CI, 5.0Y5.8 billion), with a mean total charge of $24,000 (95% CI, $23,000Y26,000) per hospitalization. Estimated total cost for these admissions was $2.2 billion (95% CI, $2.0Y2.3 billion) at a mean cost per hospital day of $1670 (95% CI, $1620Y1720). The case fatality rate was 1.4%. Table 1 demonstrates the demographic characteristics of these patients, and Table 2 presents the univariate analysis of costs associated with their hospitalizations. Important demographic findings include a peak in total number of acute pancreatitis cases in the fifth decade, increasing hospitalization rates per 1000 US population with each decade of life, and a significantly higher rate of hospitalization among blacks versus whites (Table 1) . By region, hospitalization rates were significantly higher in the South than in the Northeast or West ( Table 1 ). The proportion of cases identified in each racial group and geographic region did not change when standardized by age (data not shown). Compared with the general population, patients with acute pancreatitis had a slight tendency to come from lower income groups. Thirty percent of acute pancreatitis patients (vs 27% of the general population) came from households earning less than $36,000, and 28% (vs 26% of the general population) came from household earning $36,000 to $44,999 (P G 0.005 for both).
Costs per hospitalization were significantly higher in patients 65 years or older than in those younger than 65 years, in urban versus rural hospitals, and in teaching versus nonteaching hospitals (Table 2 , P G 0.001 for all). The lowest costs per hospitalization and hospital day were in the South (significantly lower than the Northeast and West) and in the Midwest (significantly lower than the West) ( Table 2 ). The higher costs in the Northeast were primarily because of relatively high costs in the Middle Atlantic division ($12,930 per hospitalization, $1850 per hospital day) compared with New England ($8570 per hospitalization, $1570 per hospital day), whereas the higher costs in the West were attributable to high cost in the Pacific division ($13,780 per hospitalization, $2280 per hospital day) compared with the Mountain division ($8530 per hospitalization, $1700 per hospital day). The mean LOS for the entire United States was 5.9 days (95% CI, 5.7Y6.1). Table 3 shows multivariate regression results for predictors of total costs. Model 1, which does not include LOS, demonstrates, similar to the univariate analysis, that the mean cost per hospitalization was higher for older patients, male patients, patients in urban hospitals, teaching hospitals, and Western hospitals. Increasing age raised the mean cost by 10Y14 and confirms recent work from our group that was derived from separate data sources.
2 Although cost, rather than demographic characterization, was the focus of this analysis, national data on hospital admissions for acute pancreatitis in the United States are so sparse that confirmation of the few prior analyses on this topic both buttresses our confidence in the extant literature and lends credence to our cost analysis.
Because we focused our analysis on hospitalizations with a primary diagnosis of acute pancreatitis, this study almost certainly underestimates real costs attributable to pancreatitis. Many patients who have acute pancreatitis as a complication of another malady, procedure, or medication will not have pancreatitis coded as their primary diagnosis, although it may be a major complicating factor adding morbidity and cost to their hospitalization. Our study does not capture a large number of admissions or procedures directly attributable to acute pancreatitis such as those related to interval cholecystectomy or the treatment of pseudocyst or abscess if such treatment was provided during a separate admission. Finally, costs attributable to lost work, which can be substantial in pancreatitis, 15 are not accounted for in this analysis.
Our analysis indicates that increasing age, urban location, and teaching hospital status were all associated with increased cost and that these findings were driven primarily by a longer LOS. These factors have been associated with increased cost in studies of other diseases, with the higher cost attributed to increased disease severity, expenses associated with teaching, or greater care intensity. 16Y18 In our study, these factors were linked to LOS, affirming the intuitive belief that cost is primarily dependent on LOS and that reducing LOS, if it can be done safely, would be an effective way to contain costs. Differences in LOS similarly explain the multivariate differences in cost based on region, with one exception. The association between hospitals in the western United States and cost was strong, even after controlling for LOS. This suggests that certain practice styles can result in different cost profiles for acute pancreatitis treatment. Although some of these differences may be appropriate and even reduce overall costs in the long termVsuch as performing cholecystectomy during the initial hospitalization for many cases of gallstone pancreatitisVidentification of the factors other than LOS causing increased cost will be important to limiting those costs in the future.
This study has a few potential limitations. The etiology of the pancreatitis cases in the database and the number that were recurrent could not be inferred. Similarly, severity could not be ascertained. This information would be useful for formulating prevention and treatment schemes that might reduce the numbers of US pancreatitis hospitalizations and the cost of each hospital admission, as well as for explaining some of the demographic and cost patterns we describe. Additionally, the HCUP database is useful for overall counts, cost calculations, and some procedure-related analysis, but medication and imaging data are not available. Thus, using this database alone, it is difficult to analyze potential costreduction targets in pancreatitis treatment, identify low-cost versus high-cost treatment patterns, or discover the underlying causes of the cost discrepancies we describe between certain hospital and patient groups. Finally, a significant number of records in our sample were missing data on race, which limits the strength of our finding of a high incidence of hospitalization for acute pancreatitis among US blacks.
In summary, hospitalizations for acute pancreatitis consume significant healthcare resources, with direct costs of hospitalization topping $2 billion in 2003. Older patients and patients in urban and teaching hospitals had higher costs per hospitalization, based primarily on longer LOS. Acute pancreatitis hospitalizations are significantly more common among blacks than whites in the United States, and the hospitalization rate for all patients increases with age. We believe this analysis provides useful information on the demographic characteristics of US pancreatitis patients and unique data on the costs of these hospitalizations in the United States. It provides a foundation for more detailed analyses of current cost and disease patterns and for the development of effective strategies to mitigate the medical and economic burdens of pancreatitis in the United States.
